Russell Investments Group Ltd. Lowers Stake in Solventum Corporation $SOLV

Key Points

• Russell Investments Group Ltd. sold 7,438 shares of Solventum Corporation, reducing its stake by 13.9%, with remaining shares valued at approximately $3.49 million.
• Analysts have varying ratings on Solventum, with Wells Fargo raising the target price from $75.00 to $79.00, while Wall Street Zen downgraded from "strong-buy" to "buy."
• In its recent earnings report, Solventum beat earnings expectations with $1.69 EPS compared to a consensus estimate of $1.45, and reported a revenue increase of 3.8% year-over-year.

Russell Investments Group Ltd. lessened its position in shares of Solventum Corporation (NYSE:SOLV - Free Report) by 13.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 46,053 shares of the company's stock after selling 7,438 shares during the period. Russell Investments Group Ltd.'s holdings in Solventum were worth $3,491,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SOLV. Perigon Wealth Management LLC raised its stake in Solventum by 3.8% during the first quarter. Perigon Wealth Management LLC now owns 4,352 shares of the company's stock valued at $331,000 after buying an additional 159 shares in the last quarter. SouthState Corp increased its stake in shares of Solventum by 31.9% in the first quarter. SouthState Corp now owns 699 shares of the company's stock worth $53,000 after purchasing an additional 169 shares during the period. MassMutual Private Wealth & Trust FSB boosted its holdings in Solventum by 22.3% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 937 shares of the company's stock valued at $71,000 after purchasing an additional 171 shares in the last quarter. EP Wealth Advisors LLC boosted its holdings in shares of Solventum by 3.6% in the 4th quarter. EP Wealth Advisors LLC now owns 5,272 shares of the company's stock worth $348,000 after acquiring an additional 181 shares in the last quarter. Finally, Brown Lisle Cummings Inc. raised its position in shares of Solventum by 22.0% during the 1st quarter. Brown Lisle Cummings Inc. now owns 1,038 shares of the company's stock valued at $79,000 after acquiring an additional 187 shares during the last quarter.

Analyst Upgrades and Downgrades

SOLV has been the subject of several recent analyst reports. Piper Sandler reiterated an "overweight" rating and issued a $94.00 target price (up from $87.00) on shares of Solventum in a research note on Friday, August 8th. Wall Street Zen downgraded shares of Solventum from a "strong-buy" rating to a "buy" rating in a research note on Sunday. Wells Fargo & Company upped their price objective on shares of Solventum from $75.00 to $79.00 and gave the stock an "equal weight" rating in a research report on Friday, August 8th. KeyCorp started coverage on shares of Solventum in a research note on Friday, June 6th. They set a "sector weight" rating on the stock. Finally, Morgan Stanley raised shares of Solventum from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $80.00 to $103.00 in a report on Tuesday, July 15th. Four research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $85.75.

Solventum Trading Down 0.7%

SOLV traded down $0.48 during trading on Thursday, hitting $72.42. 454,135 shares of the stock traded hands, compared to its average volume of 1,078,890. The firm has a market capitalization of $12.56 billion, a P/E ratio of 33.50, a price-to-earnings-growth ratio of 1.77 and a beta of 0.52. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86. The firm has a 50-day moving average of $73.77 and a 200 day moving average of $72.84. Solventum Corporation has a 12-month low of $60.01 and a 12-month high of $85.92.

Solventum (NYSE:SOLV - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping the consensus estimate of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The firm had revenue of $2.16 billion during the quarter, compared to analysts' expectations of $2.12 billion. During the same period last year, the company posted $1.56 EPS. The company's quarterly revenue was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Equities research analysts anticipate that Solventum Corporation will post 6.58 EPS for the current year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.